EMEA-002472-PIP02-19

Key facts

Active substance
genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII
Therapeutic area
Dermatology
Decision number
P/0227/2019
PIP number
EMEA-002472-PIP02-19
Pharmaceutical form(s)
Gel
Condition(s) / indication(s)
Treatment of dystrophic epidermolysis bullosa
Route(s) of administration
Topical use
Contact for public enquiries
Krystal Biotech, Inc.

Tel. +434 409 0176
E-mail: svinzant@krystalbio.com

Decision type
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan

Decision

How useful was this page?

Add your rating